Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach

Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T (2019)

Publication Type: Journal article, Review article

Publication year: 2019

Journal

Expert Review of Gastroenterology and Hepatology Taylor & Francis

DOI: 10.1080/17474124.2019.1645595

Abstract

Introduction: The purpose of this review is to highlight the role of biosimilars in early treatment in IBD and introduce ways to facilitate a patient-centric switching process through multidisciplinary approach. Areas covered: We summarize existing scientific literature related to the role of biosimilars in inflammatory bowel disease in terms of early treatment and cost-saving and implementing switching process. Expert opinion: Use of anti-TNF biosimilars in patients has the potential for large drug-acquisition cost-saving, which can be reinvested into early treatment. Managed switched programs for adalimumab can add further benefits in the future.

Authors with CRIS profile

Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)

Involved external institutions

University Hospital Southampton NHS

United Kingdom (GB) Biogen International GmbH

Switzerland (CH) Istituto Clinico Humanitas

Italy (IT) Université de Lorraine

France (FR) Samsung Bioepis

Korea, Republic of (KR) Royal Free Hospital

United Kingdom (GB)

How to cite

APA:

Peyrin-Biroulet, L., Danese, S., Cummings, F., Atreya, R., Greveson, K., Pieper, B., & Kang, T. (2019). Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. Expert Review of Gastroenterology and Hepatology. https://doi.org/10.1080/17474124.2019.1645595

MLA:

Peyrin-Biroulet, Laurent, et al. "Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach." Expert Review of Gastroenterology and Hepatology (2019).

BibTeX: Download